Dynorphin acts as a neuromodulator to inhibit itch in the dorsal horn of the spinal cord.
Kardon AP, Polgár E, Hachisuka J, Snyder LM, Cameron D, Savage S, Cai X, Karnup S, Fan CR, Hemenway GM, Bernard CS, Schwartz ES, Nagase H, Schwarzer C, Watanabe M, Furuta T, Kaneko T, Koerber HR, Todd AJ, Ross SE. · 2014
Read Dynorphin acts as a neuromodulator to inhibit itch in the dorsal horn of the spinal cord. by Kardon AP, Polgár E, Hachisuka J, Snyder LM, Cameron D, Savage S, Cai X, Karnup S, Fan CR, Hemenway GM, Bernard CS, Schwartz ES, Nagase H, Schwarzer C, Watanabe M, Furuta T, Kaneko T, Koerber HR, Todd AJ, Ross SE. (2014) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc4022838.txt.
Introduction
Adam P. Kardon and a large team of co-authors find a spinal brake on itch, in Neuron in 2014. Scratching aids such as menthol calm itch for minutes to hours, but the nerve basis was unknown. Mice lacking a set of spinal brake cells, called B5-I neurons, develop severe lasting itch.
The cells form a distinct chemical subset of brake neurons in the spinal cord's dorsal horn. Turning them off or losing them let itch run free, while their normal action held itch down. They release a compound called dynorphin, a key itch damper. Sensory fibres that answer to menthol, capsaicin, and mustard oil feed into these cells, and mice without the cells lost menthol's calming effect. The work gives a cell basis for how counter-stimuli quiet itch, and suggests a drug class, kappa opioids, as a fresh route for hard chronic itch.
Catalog record
| CREATOR | Kardon AP, Polgár E, Hachisuka J, Snyder LM, Cameron D, Savage S, Cai X, Karnup S, Fan CR, Hemenway GM, Bernard CS, Schwartz ES, Nagase H, Schwarzer C, Watanabe M, Furuta T, Kaneko T, Koerber HR, Todd AJ, Ross SE. |
|---|---|
| YEAR | 2014 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 56 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Dynorphin Acts as a Neuromodulator to Inhibit Itch in the Dorsal Horn of the Spinal Cord By Adam P. Kardon, Erika Polgár, Junichi Hachisuka, Lindsey M. Snyder, Darren Cameron, Sinead Savage, Xiaoyun Cai, Sergei Karnup, Christopher R. Fan, Gregory M. Hemenway, Carcha S. Bernard, Erica S. Schwartz Published in: Neuron DOI: 10.1016/j.neuron.2014.02.046 ABSTRACT Summary Menthol and other counterstimuli relieve itch, resulting in an antipruritic state that persists for minutes to hours. However, the neural basis for this effect is unclear, and the underlying neuromodulatory mechanisms are unknown. Previous studies revealed that Bhlhb5−/− mice, which lack a specific population of spinal inhibitory interneurons (B5-I neurons), develop pathological itch. Here we characterize B5-I neurons and show that they belong to a neurochemically distinct subset. We provide cause-and-effect evidence that B5-I neurons inhibit itch and show that dynorphin, which is released from B5-I neurons, is a key neuromodulator of pruritus. Finally, we show that B5-I neurons are innervated by menthol-, capsaicin-, and mustard oil-responsive sensory neurons and are required for the inhibition of itch by menthol. These findings provide a cellular basis for the inhibition of itch by chemical counterstimuli and suggest that kappa opioids may be a broadly effective therapy for pathological itch. INTRODUCTION Itch, like pain, is an aversive sensation that warns us of potential threats to the body (Ross, 2011; Bautista et al., 2014). However, itch is a distinct sensation, characterized by the desire to scratch. Although scratching may remove irritants from the skin (providing at least transient relief from itch), it has the paradoxical effect of causing tissue damage that potentiates itch through release of inflammatory mediators. This pathological itch-scratch-itch cycle is a hallmark of chronic pruritus, which can be just as debilitating as chronic pain (Weisshaar and Dalgard, 2009; Yosipovitch, 2008). Unfortunately, there are few therapeutic options for those that suffer from severe pathological itch. Whereas mu opioids such as morphine are highly effective for the treatment of pain, these drugs actually worsen itch (Ko and Naughton, 2000; Szarvas et al., 2003). Thus, there is a great need for better therapies to treat intractable pruritus. One reason that itch has lagged behind pain in terms of effective therapies is because, until recently, we lacked a clear understanding of how itch is detected and encoded in the nervous system. However, over the last few years there has been much progress in this field. There is now good evidence that MrgprA3-expressing sensory neurons selectively mediate itch, even when activated by the classic algogen capsaicin (Han et al., 2013). It is very likely that these are not the only itch-selective fibers, since histamine-dependent itch appears to be mediated by a different subset of sensory neurons (Roberson et al., 2013). Next, itch seems to be relayed by at least two populations of spinal interneurons—those that express the Npra receptor and those that express the gastrin-releasing peptide receptor (GRPR)—before being conveyed to the brain where it is consciously perceived (Mishra and Hoon, 2013; Sun et al., 2009). Menthol and other forms of counterstimulation, such as scratching, heat, cool, and noxious agents, provide relief of itch that begins almost instantaneously and lasts from minutes to hours (Ward et al., 1996; Yosipovitch et al., 2007; Bromm et al., 1995). This relief occurs even when the counterstimulus is applied at great distances from the source of itch sensation (Nilsson et al., 1997). Together, these psychophysical observations suggest that crossmodal inhibition occurs centrally, possibly within the spinal dorsal horn, where sensory information is first integrated and modulated (Todd, 2010). The instantaneous relief of itch experienced upon scratching is presumably mediated by a fast-acting neurotransmitter (Akiyama et al., 2011). In contrast, prolonged inhibition is thought to involve neuromodulators, but the nature of such neuromodulation remains elusive and the neural basis for inhibition of itch by counterstimuli is not known. We previously generated a mouse model of pathological chronic itch through the constitutive deletion of Bhlhb5 (also known as Bhlhe22), a transcription factor that is transiently expressed in several neuronal subtypes during embryonic and early postnatal development (Ross et al., 2010, 2012). Through selective ablation, we provided strong evidence that the pathological itch in Bhlhb5 mutant mice was due to loss of Bhlhb5 in inhibitory neurons in the spinal dorsal horn. Using fate-mapping approaches, we found that Bhlhb5 mutant mice lack a subset of inhibitory neurons in laminae I and II (Ross et al., 2010). These findings suggested that Bhlhb5 is essential for the survival of a set of spinal inhibitory interneurons (termed B5-I neurons) that are required for normal itch sensation. However, the identity of B5-I neurons was not clear, and how they inhibit itch was not known. Here we provide evidence that acute inhibition of B5-I neurons results in elevated itch. We identify and characterize B5-I neurons, showing that they correspond to specific neurochemically defined populations and that they release the kappa opioid dynorphin. Our data suggest that kappa agonists act locally within the spinal cord to selectively reduce itch and not pain. We find that B5-I cells are directly innervated by primary afferents that respond to counterstimuli, such as heat and coolness, which relieve itch in humans. Moreover, we show that menthol inhibits itch in wild-type mice but does not do so in mice lacking B5-I neurons. Thus, B5-I neurons may mediate the inhibition of itch by chemical counterstimuli. RESULTS Acute Inhibition of B5-I Cells Results in Elevated Itch We previously showed that Bhlhb5 is needed for survival of spinal inhibitory interneurons that are required for normal itch sensation (Ross et al., 2010). To more specifically identify these neurons, we performed coimmunostaining for Bhlhb5 and markers that define distinct populations of spinal interneurons. Bhlhb5 is transiently expressed in ∼7% of neurons in the dorsal horn of mice from embryonic day 13.5 to postnatal day 10 (P10), so we performed these experiments using P4 mice. Consistent with our previous report (Ross et al., 2010), we found that three-quarters of Bhlhb5-expressing neurons in superficial dorsal horn (laminae I and II) are inhibitory, as shown by coexpression of Pax2 (Figure 1A). We refer to these Bhlhb5-expressing inhibitory interneurons as B5-I neurons. The somatostatin receptor sst2A is exclusive to inhibitory neurons in superficial dorsal horn and is found in ∼50% of the inhibitory interneurons in this region (Polgár et al., 2013a, 2013b; Todd et al., 1998; Yasaka et al., 2010). To determine whether the B5-I neurons belonged to this subset, we used antibodies against Bhlhb5, Pax2, and sst2A. This immunostaining showed that the vast majority of B5-I neurons (∼90%) coexpressed the somatostatin receptor sst2A (Figures 1A and S1A available online). Furthermore, when we recorded from spinal interneurons genetically labeled with the Bhlhb5-cre allele (Ross et al., 2010), half showed strong hyperpolarization in response to somatostatin (Figure 1B), confirming that B5-I neurons express functional sst2A receptors. Given the loss of B5-I neurons in Bhlhb5−/− mice, we reasoned that there would be a corresponding decrease in the number of sst2A-expressing neurons in these animals. As predicted, the number of sst2A-expressing neurons was reduced by two-thirds in Bhlhb5−/− mice, with no significant change in the number of sst2A-negative inhibitory neurons (Figures 1C and 1D). Thus, the vast majority of B5-I neurons belong to the subset of inhibitory spinal interneurons that express sst2A, and